BRCA1 and ovarian cancer: This integration, although less efficient (0.2–1%) compared to HEK293T, was specific as all sorted cells exhibited correct Rab11a/b localization, and our protocol was also successful in a second ovarian cancer cell line that has defective homologous recombination (BRCA-1 mutant COV362 Beaufort et al., 2014; Figure 1E).